within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M01A_AntiinflammatoryAndAntirheumaticProductsNonStero.M01AB15_Ketorolac;

model Ketorolac_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 6.805555555555556e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.013,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.023166666666666665,
    Tlag = 540,
    Vdp = 0.0081,
    k12 = 9.527777777777778e-06,
    k21 = 9.527777777777778e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ketorolac_1</td></tr><tr><td>ATC code:</td><td>M01AB15_1</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>13</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.35</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) commonly used for the short-term treatment of moderate to severe pain. It is typically administered for post-operative pain management and is not recommended for long-term use due to potential side effects, particularly on the gastrointestinal tract and kidneys. Ketorolac is approved and used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adults after oral administration.</p><h4>References</h4><ol><li><p>Mandema, JW, &amp; Stanski, DR (1996). Population pharmacodynamic model for ketorolac analgesia. <i>Clinical pharmacology and therapeutics</i> 60(6) 619–635. DOI:<a href=\"https://doi.org/10.1016/S0009-9236(96)90210-6\">10.1016/S0009-9236(96)90210-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8988064/\">https://pubmed.ncbi.nlm.nih.gov/8988064</a></p></li><li><p>Pate, J, et al., &amp; Gould, S (2022). Efficacy of outpatient infusion therapy in pediatric patients with postconcussive headaches. <i>Child&#x27;s nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery</i> 38(1) 103–108. DOI:<a href=\"https://doi.org/10.1007/s00381-021-05383-6\">10.1007/s00381-021-05383-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34671849/\">https://pubmed.ncbi.nlm.nih.gov/34671849</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M01AB15_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ketorolac_1;
